Corbus Pharmaceuticals
CRBP
64 hedge funds and large institutions have $3.86M invested in Corbus Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 14 reducing their positions, and 12 closing their positions.
110% more call options, than puts
Call options by funds: $65K | Put options by funds: $31K
0.22% less ownership
Funds ownership: 0.85% → 0.62% (-0.22%)
9% less funds holding
Funds holding: 70 → 64 (-6)
29% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 14
42% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 12
52% less capital invested
Capital invested by funds: $8.04M → $3.86M (-$4.18M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
ExodusPoint Capital Management
New York
|
+$85.2K |
| 2 |
Two Sigma Investments
New York
|
+$10.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$9.53K |
| 4 |
KCIA
Kingsbury Capital Investment Advisors
Wilmette,
Illinois
|
+$7.92K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$7.29K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$853K |
| 2 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$553K |
| 3 |
Renaissance Technologies
New York
|
-$197K |
| 4 |
IEFM
IQ EQ Fund Management
Dublin 2,
Ireland
|
-$115K |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$109K |
CRBP Hedge Fund Activity: Q3 2022 in Review
64 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q3 2022, worth a combined $3.86M — down 52% from $8.04M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of CRBP and 7 opened new positions — a net loss of 5 holders — while 14 trimmed existing stakes and 10 added.
The largest buyer was ExodusPoint Capital Management, opening a new position worth an estimated $85.2K. The largest seller was Mirae Asset Global Investments, cutting an estimated $853K.
- 64 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q3 2022, down from 70 in Q2 2022.
- Funds reported $3.86M of Corbus Pharmaceuticals stock for Q3 2022, down 52% quarter-over-quarter.
- 7 funds opened new Corbus Pharmaceuticals positions in Q3 2022 and 12 closed out, a net change of -5 holders.
- The largest Corbus Pharmaceuticals buyer in Q3 2022 was ExodusPoint Capital Management, an estimated $85.2K added.
- The largest Corbus Pharmaceuticals seller in Q3 2022 was Mirae Asset Global Investments, an estimated $853K sold.
Based on aggregated 13F filings for Q3 2022.